United States-based Akero Therapeutics Inc. (Nasdaq: AKRO), has received Priority Medicines (PRIME) designation from the European Medicines Agency (EMA) for efruxifermin (EFX), an investigational FGF21 analogue, intended for the treatment of non-alcoholic steatohepatitis (NASH), a non-alcoholic fatty liver disease, it was reported on Friday.
The product was granted the designation based on the positive efficacy data recently reported from the company's Phase 2a BALANCED study.
The firm is planning to start a Phase 2b/3 adaptive trial of EFX in biopsy-confirmed NASH patients in the first half of 2021, based on guidance received from the United States Food and Drug Administration (FDA).
DATROWAY receives US priority review for first-line metastatic triple negative breast cancer
Lupin launches Dasatinib tablets in US market
Natera submits Signatera CDx PMA to FDA for bladder cancer use
Pharming receives FDA complete response letter for paediatric Joenja application
Trace Biosciences' IND application for nerve-specific imaging agent approved by FDA
Frontage expands early phase clinical research capabilities across US and China
MicuRx Pharmaceuticals' IND application for MRX-5 cleared by FDA
FDA approves Tenpoint Therapeutics' YUVEZZI as first dual-agent eye drop for presbyopia
Summit Therapeutics' BLA for ivonescimab in EGFR-mutated NSCLC accepted by FDA
WuXi Biologics collaborates with Sinorda Biomedicine for antibody development
Biogen's litifilimab receives FDA Breakthrough Therapy Designation for CLE
Glaukos receives FDA approval for repeat administration of iDose TR
Guerbet's contrast agent Elucirem approved by European Commission in children from birth
Spine Innovation's LOGIC Titanium Implant System receives US FDA 510(k) market approval